Qurient Co. Ltd (115180) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Qurient Co. Ltd (115180) has a cash flow conversion efficiency ratio of -0.062x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-3.15 Billion ≈ $-2.13 Million USD) by net assets (₩50.69 Billion ≈ $34.35 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Qurient Co. Ltd - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how Qurient Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read 115180 liabilities breakdown for a breakdown of total debt and financial obligations.
Qurient Co. Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Qurient Co. Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Zhejiang Changhua Auto Parts Co Ltd
SHG:605018
|
0.048x |
|
Eczacibasi Yatirim Holding Ortakligi AS
IS:ECZYT
|
0.001x |
|
Varroc Engineering Limited
NSE:VARROC
|
0.212x |
|
Minerals 260 Ltd
AU:MI6
|
-0.038x |
|
Aucma Co Ltd
SHG:600336
|
0.257x |
|
Qingdao Eastsoft Communic Tech
SHE:300183
|
0.004x |
|
People & Technology Inc
KQ:137400
|
0.023x |
|
SMU S.A
SN:SMU
|
0.071x |
Annual Cash Flow Conversion Efficiency for Qurient Co. Ltd (2014–2024)
The table below shows the annual cash flow conversion efficiency of Qurient Co. Ltd from 2014 to 2024. For the full company profile with market capitalisation and key ratios, see market cap of Qurient Co. Ltd.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩57.60 Billion ≈ $39.03 Million |
₩-23.32 Billion ≈ $-15.80 Million |
-0.405x | +14.10% |
| 2023-12-31 | ₩46.62 Billion ≈ $31.59 Million |
₩-21.97 Billion ≈ $-14.89 Million |
-0.471x | +33.78% |
| 2022-12-31 | ₩35.14 Billion ≈ $23.81 Million |
₩-25.00 Billion ≈ $-16.94 Million |
-0.712x | -57.89% |
| 2021-12-31 | ₩54.08 Billion ≈ $36.65 Million |
₩-24.37 Billion ≈ $-16.52 Million |
-0.451x | -28.45% |
| 2020-12-31 | ₩56.57 Billion ≈ $38.33 Million |
₩-19.85 Billion ≈ $-13.45 Million |
-0.351x | +74.59% |
| 2019-12-31 | ₩17.38 Billion ≈ $11.78 Million |
₩-24.00 Billion ≈ $-16.26 Million |
-1.381x | -294.23% |
| 2018-12-31 | ₩39.41 Billion ≈ $26.70 Million |
₩-13.80 Billion ≈ $-9.36 Million |
-0.350x | +59.55% |
| 2017-12-31 | ₩14.53 Billion ≈ $9.85 Million |
₩-12.59 Billion ≈ $-8.53 Million |
-0.866x | -113.10% |
| 2016-12-31 | ₩24.35 Billion ≈ $16.50 Million |
₩-9.90 Billion ≈ $-6.71 Million |
-0.406x | +84.40% |
| 2015-12-31 | ₩2.89 Billion ≈ $1.96 Million |
₩-7.54 Billion ≈ $-5.11 Million |
-2.605x | -950.52% |
| 2014-12-31 | ₩-21.68 Billion ≈ $-14.69 Million |
₩-6.64 Billion ≈ $-4.50 Million |
0.306x | -- |
About Qurient Co. Ltd
Qurient Co., Ltd., a biotech company, engages in the research and development of drugs to address unmet medical needs in Korea and internationally. The company's pipeline products include Q301, a topical 5LO inhibitor, which is in Phase II clinical trial for the treatment of atopic dermatitis; and Telacebec (Q203), Cyt bc1 Inhibitor, that is in Phase II to treat Mycobacterial Infections, such as … Read more